Literature DB >> 17947278

A new cell line from a recurrent conjunctival melanoma.

Sander Keijser, Willem Maat, Guy S Missotten, Rob J W de Keizer.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17947278      PMCID： PMC2095439          DOI： 10.1136/bjo.2006.110841

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  4 in total

1.  Establishment of two cell lines derived from conjunctival melanomas.

Authors:  Gordon Nareyeck; Henrike Wuestemeyer; Daniela von der Haar; Gerasimos Anastassiou
Journal:  Exp Eye Res       Date:  2005-09       Impact factor: 3.467

Review 2.  Conjunctival melanoma.

Authors:  S Seregard
Journal:  Surv Ophthalmol       Date:  1998 Jan-Feb       Impact factor: 6.048

3.  Conjunctival melanoma in the Netherlands: a nationwide study.

Authors:  Guy S Missotten; Sander Keijser; Rob J W De Keizer; Didi De Wolff-Rouendaal
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

4.  Establishment and characterization of human ocular melanoma cell lines.

Authors:  C Aubert; F Rouge; M Reillaudou; P Metge
Journal:  Int J Cancer       Date:  1993-07-09       Impact factor: 7.396
  4 in total
  8 in total

1.  Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.

Authors:  Nadine E de Waard; Paraskevi E Kolovou; Sean P McGuire; Jinfeng Cao; Natasha Y Frank; Markus H Frank; Martine J Jager; Bruce R Ksander
Journal:  Ocul Oncol Pathol       Date:  2015-04

2.  IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.

Authors:  Dawei Song; Sonia Cismas; Caitrin Crudden; Eric Trocme; Claire Worrall; Naida Suleymanova; Tingting Lin; Huiyuan Zheng; Stefan Seregard; Ada Girnita; Leonard Girnita
Journal:  Oncogene       Date:  2021-11-17       Impact factor: 9.867

3.  Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model.

Authors:  Quanchi Chen; Jordi-Amat Cuello-Garibo; Ludovic Bretin; Liyan Zhang; Vadde Ramu; Yasmin Aydar; Yevhen Batsiun; Sharon Bronkhorst; Yurii Husiev; Nataliia Beztsinna; Lanpeng Chen; Xue-Quan Zhou; Claudia Schmidt; Ingo Ott; Martine J Jager; Albert M Brouwer; B Ewa Snaar-Jagalska; Sylvestre Bonnet
Journal:  Chem Sci       Date:  2022-05-16       Impact factor: 9.969

4.  Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Authors:  Martine J Jager; Robert M Verdijk; Jinfeng Cao; Renier C Heijkants; Aart G Jochemsen; Mehmet Dogrusöz; Mark J de Lange; Pieter A van der Velden; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-07-22

5.  Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.

Authors:  Jinfeng Cao; Kelly Cs Pontes; Renier C Heijkants; Niels J Brouwer; Arwin Groenewoud; Ekaterina S Jordanova; Marina Marinkovic; Sjoerd van Duinen; Amina Fas Teunisse; Robert M Verdijk; Ewa Snaar-Jagalska; Aart G Jochemsen; Martine J Jager
Journal:  J Pathol       Date:  2018-06-23       Impact factor: 7.996

6.  Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway.

Authors:  Keting Bao; Yongyun Li; Jinlian Wei; Ruoxi Li; Jie Yang; Jiahao Shi; Baoli Li; Jin Zhu; Fei Mao; Renbing Jia; Jian Li
Journal:  Cell Death Dis       Date:  2021-04-07       Impact factor: 8.469

7.  PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

Authors:  Jinfeng Cao; Niels J Brouwer; Kate E Richards; Marina Marinkovic; Sjoerd van Duinen; Daan Hurkmans; Els M E Verdegaal; Ekaterina S Jordanova; Martine J Jager
Journal:  Oncotarget       Date:  2017-05-20

8.  TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models.

Authors:  Quanchi Chen; Vadde Ramu; Yasmin Aydar; Arwin Groenewoud; Xue-Quan Zhou; Martine J Jager; Houston Cole; Colin G Cameron; Sherri A McFarland; Sylvestre Bonnet; B Ewa Snaar-Jagalska
Journal:  Cancers (Basel)       Date:  2020-03-04       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.